Paroxysmal Nocturnal Hemoglobinuria Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Paroxysmal Nocturnal Hemoglobinuria remains an active clinical development field. One-time and precision therapies are raising the efficacy ceiling, but durability, manufacturing, small-population evidence and long-term safety remain decisive constraints. The PatSnap evidence set used here contains 103 matched trial records and 290 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| CTR20262609 | HS-10542 | Phase 1; 进行中 （尚未招募） | Shanghai Hansoh Biomedical Co. Ltd.; Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | China | (Day 1~Day 21) | Timing not listed |
| CTR20262505 | NTQ5082 + Midazolam | Phase 1; 进行中 （尚未招募） | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | China | (研究期间) | Timing not listed |
| ChiCTR2600126558 | CG-001(ComGen) | Phase 2; Not yet recruiting | Peking Union Medical College Hospital; Beijing Union Medical College Hospital, Chinese Academy of Medical Sciences; Hematology Hospital of Chinese Academy of Medical Sciences | China | The proportion of participants who had an Hb increase of >=20 g/L compared with baseline in at least 3 of the 4 tests during the treatment period from week 18 to week 24, without red blood cell transfusion after 2 weeks of treatment. | 2027-04-21 |
| CTR20261735 | CG-001(ComGen) | Phase 2; 进行中 （尚未招募） | Shanghai Kangjing Biomedical Technology Co., Ltd. | China | (第18周至24周) | Timing not listed |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- A Phase 3, Single-arm, Open-label, Multicenter Study to Assess the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Complement Inhibitor Treatment Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China (Phase 3): the indexed record reports Percentage Change in Lactate Dehydrogenase (LDH) From Baseline to Day 183 (Week 26)(Least Squares Mean) = -81.3 percent change (95% Confidence Interval, -84.2 to -78.3); Percentage Change in Lactate Dehydrogenase (LDH) From Baseline to Day 183 (Week 26)(Least Squares Mean): P-Value = < 0.001; Percentage Change in Lactate Dehydrogenase (LDH) From Baseline to Day 183 (Week 26)(Least Squares Mean): P-Value = < 0.001.
- Open-Label, Multicenter Study to Assess the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Complement Inhibitor Treatment Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China (Phase 3): the indexed record reports Percentage Change From Baseline in LDH at Week 12(Least Squares Mean) = -76.5 percentage change (95% Confidence Interval, -87.8 to -65.2); Percentage Change From Baseline in LDH at Week 12(Least Squares Mean): P-Value = <0.001; Percentage Change From Baseline in LDH at Week 12(Least Squares Mean): P-Value = <0.001.
- RAVULIZUMAB MAINTAINS OR IMPROVES RENAL FUNCTION IN REAL-WORLD PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (Not Applicable): the indexed record reports CKD stage(maintained or improved) = 87.0 %; CKD stage(maintained or improved) = 89.0 %.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including HS-10542 (Phase 2; CFB), NTQ5082 (Phase 3; CFB), Midazolam (Approved; GABAA receptor), CG-001(ComGen) (Phase 2; C3b). Company & Deal Intelligence records identify sponsor context for Shanghai Hansoh Biomedical Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., Peking Union Medical College Hospital, Beijing Union Medical College Hospital, Chinese Academy of Medical Sciences. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Natural-history-aligned endpoints that remain interpretable in small heterogeneous cohorts.
- Long-term registries for durability, immunogenicity and delayed safety signals.
- Redosing, rescue and treatment-sequencing strategies after incomplete response.
- Access models that address diagnosis, manufacturing and global delivery.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Paroxysmal Nocturnal Hemoglobinuria has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
